Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.
Yan-Hui LuoJun YangAng WeiGuang-Hua ZhuBin WangRui ZhangChen-Guang JiaYan YanKai WangSidan LiXuan ZhouMao-Quan QinTian-You WangPublished in: World journal of pediatrics : WJP (2021)
Haploidentical hematopoietic stem cell transplantation is safe and effective in the treatment of pediatric CAEBV and can be used as an alternative therapy without matched donors or emergency transplantation. Patients with active disease before HSCT also benefited from haplo-HSCT. Haplo-HSCT requires careful monitoring for complications, such as GVHD and TMA. Early detection of TMA and timely treatment can reduce mortality and can improve the survival rate.
Keyphrases
- epstein barr virus
- stem cell transplantation
- bone marrow
- acute myeloid leukemia
- emergency department
- healthcare
- public health
- diffuse large b cell lymphoma
- risk factors
- hematopoietic stem cell
- peripheral blood
- stem cells
- type diabetes
- cardiovascular disease
- mesenchymal stem cells
- coronary artery disease
- replacement therapy
- acute lymphoblastic leukemia
- kidney transplantation
- combination therapy
- allogeneic hematopoietic stem cell transplantation